• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zeus Names New Chief Executive Officer

    3/14/24 1:00:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    • Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO

       
    • O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership

       
    • O'Brien currently serves as Worldwide President of BD Peripheral Intervention

    ORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.

    Incoming CEO, Zeus

    Zeus Names New Chief Executive Officer - Padraic "Paddy" O'Brien

    O'Brien is currently Worldwide President of BD Peripheral Intervention at Becton, Dickinson, and Company (NYSE:BDX), a medical technology company focused on advancing clinical therapy for patients and clinical process for healthcare providers.

    Before that, he held various leadership positions within BD, where he developed an extensive and consistent track record of delivering durable, sustainable growth while creating a winning culture. From 2001-2016, he held a series of ascending management positions within Bard until BD acquired the company in December 2017.

    O'Brien holds a Bachelor of Science in Combined Sciences (Biology and Chemistry) from Santa Clara University.

    Ethan Waxman, Partner within EQT Private Equity's Advisory Team, said: "We undertook an extensive search to find Zeus' next CEO, and Paddy's deep domain knowledge and experience make him perfectly suited to lead the company through this next phase of growth. We look forward to partnering with Paddy as we make significant investments in increased capacity, process improvement, and product innovation."

    "We are thrilled to welcome Paddy as the new CEO of Zeus," said John Groetelaars, Executive Chairman at Zeus. "He has deep insights and a keen understanding of the interventional markets targeted by Zeus' customers. His extensive experience and proven track record make him the ideal leader to steer Zeus through this exciting chapter of growth and advancement."

    About Zeus

    Zeus, headquartered in Orangeburg, South Carolina, is the world's leading polymer extrusion and catheter design manufacturer. With over 55 years of experience in medical, aerospace, energy, automotive, fiber optics, and other leading industries, Zeus' mission is to provide solutions, enable innovation, and enhance lives. The company employs over 2,400 people worldwide with facilities in Aiken, Columbia, Gaston, and Orangeburg, South Carolina; Branchburg, New Jersey; Chattanooga, Tennessee; San Jose, California; Arden Hills, Minnesota; and Letterkenny, Ireland. For more information, visit www.zeusinc.com.

    Zeus logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zeus-names-new-chief-executive-officer-302089568.html

    SOURCE Zeus Company, LLC

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2024/14/c9154.html

    Get the next $BDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    5/1/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Becton Dickinson with a new price target

    RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00

    9/25/25 8:27:46 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Citigroup with a new price target

    Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

    5/22/25 8:18:13 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

    5/2/25 8:06:47 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scott Bertram L sold $38,318 worth of shares (217 units at $176.58), decreasing direct ownership by 0.60% to 35,816 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/7/25 5:36:46 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Byington Carrie L

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/4/25 8:41:02 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Jones Christopher Ian Montague

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/4/25 8:36:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    11/17/25 4:34:49 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    11/6/25 6:32:28 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    10/15/25 4:18:58 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification

    RANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that the Conformité Européenne (CE) Marked BD Onclarity™ HPV Assay for the BD COR™ System and the BD Viper™ LT System have been accepted for the World Health Organization (WHO) list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical cancer screening tools in low- and middle-income countries. The newly prequalified assay detects 14 high-risk human papillomavirus (HPV) types, in

    11/17/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Duncan Regional Hospital Becomes First in U.S. to Implement BD Alaris™ EMR Infusion Interoperability with MEDITECH

    FRANKLIN LAKES, N.J., Nov. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Duncan Regional Hospital ("DRH Health") has become the first hospital in the United States to implement BD Alaris™ EMR (Electronic Medical Record) Interoperability with the MEDITECH electronic health record (EHR), marking a significant advancement in patient safety, workflow efficiency and clinician support. This integration brings together BD's robust market-leading bi-directional infusion interoperability – now l

    11/13/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

    FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.

    7/7/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organicQ4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectivelyFY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organicFY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6%FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD ExcellenceFY25 GAAP operating margin down 10 basis points to 11.8%; adjusted operating margin up 80 basis points to 25.0%Returned $2.2 billion to shareholders in FY25 through dividends and share repurchasesCompany issues FY26 guidanceFRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNew

    11/6/25 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Increases Dividend for 54th Consecutive Year

    FRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December 8, 2025. The indicated annual dividend rate for fiscal year 2026 is $4.20 per share. "This is the 54th consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc

    11/6/25 6:25:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Announces CFO Transition Plan

    Provides Preliminary Revenue for Fourth Quarter and Full Year Fiscal 2025  FRANKLIN LAKES, N.J., Oct. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today a transition plan under which Chris DelOrefice, executive vice president and chief financial officer (CFO), will depart the company effective Dec. 5, 2025, to pursue a new professional opportunity. The company is conducting a search to identify a permanent successor. Vitor Roque, senior vice president of finance, business units and corporate financial planning and analysis, has been named interim CFO and will assume the role effective upon DelOrefice's departur

    10/15/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care